MDxHealth (MDXH)
NASDAQ:MDXH
Want to see MDXH full AI Analyst Report?
Earnings Data
Report Date
Aug 20, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.Company Guidance
Pro Forma Q1 Revenue Growth
Pro forma revenue for the core prostate cancer operations (excluding Resolve) was $23.9 million for Q1 2026, representing an 11% year-over-year increase and demonstrating continued commercial execution of the integrated sales team.
Updated 2026 Revenue Guidance — Strong Growth Outlook
Company established 2026 revenue guidance for the core cancer business (excluding Resolve) of $110 million to $115 million, implying 20% to 26% year-over-year growth for the core cancer portfolio.
Successful Commercial Integration and Customer Migration
Completed Exo-driven strategic mapping and cross-training of the expanded sales force in Q1 and successfully transitioned SelectMDx customers to Exo, creating operating efficiencies and enabling sales reps to focus 100% on the prostate cancer menu (Confirm, GPS, ExoDx).
AI and Clinical Innovation Initiatives
Launched an AI-dedicated strategic initiative and partnerships to build an AI data platform across the company; PROTECT trial with University of Oxford now includes AI-enhanced endpoints to improve prognostic value of GPS, supporting long-term product differentiation.
Solid Reported Cash Balance (Pre-Earn-Out)
Reported cash and cash equivalents of $43.2 million as of March 31, 2026, providing near-term liquidity; after the $15.0 million earn-out payment made April 15, pro forma cash would be $28.2 million.
Historical Operational Transformation
Company highlighted multi-year progress transforming revenue from $11 million in 2019 to $108 million in 2025, expanding gross margins from the 20s to the mid-60s and achieving adjusted EBITDA profitability prior to the ExoDx acquisition.
MDXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.95 | $0.98 | -49.54% |
Feb 26, 2026 | $3.55 | $3.40 | -4.23% |
Nov 12, 2025 | $4.12 | $3.97 | -3.64% |
Aug 05, 2025 | $2.49 | $2.75 | +10.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on Aug 20, 2026, Before Open (Confirmed).
What is MDxHealth (MDXH) earnings time?
MDxHealth (MDXH) earnings time is at Aug 20, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXH EPS forecast?
MDXH EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.